Our Partners
[lsp_slider slider=our_partners]
Wipro GE Healthcare is keen to invest in technologies that are affordable to all.
Terri Bresenhem, President and Chief Executive, GE Healthcare, told reporters here on Wednesday that the company has not only been expanding its presence in India for over two decades now, but investing at least 30 per cent more in recent years. “The investment is both in terms of manpower and strengthening our research and development facility,” she said.
INDIA MANUFACTURE
“We are striving to make healthcare affordable to all. While most medical equipment companies that have established their presence here import close to 80 per cent of their equipment, our import component is less. At GE Healthcare, we design and manufacture 30 per cent of the equipment in India. We have a strong research team, high quality thinkers and innovators here,” she added.
Berlin, January 3, 2013 – Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase III trial of Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement in progression-free survival. The study, called DECISION, evaluated the efficacy and safety of Nexavar compared to placebo. The safety and tolerability were generally consistent with the known profile of Nexavar. Detailed efficacy and safety analysis from this study are expected to be presented at an upcoming medical meeting. Effective treatment options are urgently needed for patients with RAI-refractory differentiated thyroid cancer,” said Dimitris Voliotis, MD, Vice President, Global Clinical Development Oncology, Bayer HealthCare. “We are pleased that the results of this study demonstrate that Nexavar may provide a treatment option for these patients.
[lsp_slider slider=our_partners]